Synthesis of a Selective Orexin 1 Receptor Antagonist: Development of a Manufacturing Process–Part 1

In campaign 1, 103.9 kg of (S)-2-(N-benzyl-N-methylamino)-1-propanamine d-tartaric acid salt (4) was prepared in 3 stages from l-alaninamide·HCl. The Stage 2 reaction, the reductive amination of (S)-2-benzylaminopropionamide (2) with aqueous formalin using H2, Pd/C, and THF as solvent, proved to be nonrobust. Ahead of campaign 2, the Stage 2 and 3 processes were redeveloped to provide a higher yielding and more robust set of reaction conditions. The key change was to conduct the reductive amination of (S)-2-benzylaminopropionamide (2) with aqueous formalin using NaBH4 in MeOH as solvent while maintaining a constant pH (pH = 8.5) by the addition of acetic acid. In campaign 2, (S)-2-(N-benzyl-N-methylamino)-1-propanamine was isolated as the d-mandelic acid salt. A total of 373 kg of (S)-2-(N-benzyl-N-methylamino)-1-propanamine d-mandelic acid salt was produced in high yield and excellent quality. (S)-2-(N-Benzyl-N-methylamino)-1-propanamine is a key intermediate in the synthesis of the orexin 1 receptor antagonist C4X3256.

Authors

Institutions

Publication Details

Journal
Organic Process Research & Development
Published
2026-11-18
DOI
https://doi.org/10.1021/acs.oprd.6c00296
Citations
3
Primary Topic
Chemical Synthesis and Analysis
Type
article
Field-Weighted Citation Impact
3.78
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Synthesis of a Selective Orexin 1 Receptor Antagonist: Development of a Manufacturing Process–Part 1

Jonathan C. Churchill, Paul Leong, James D. Firth, John S Carey et al.
3 citations
Organic Process Research & Development
Chemical Synthesis and Analysis
3.78
article

Synthesis of a Selective Orexin 1 Receptor Antagonist: Development of a Manufacturing Process–Part 1

Jonathan C. Churchill, Paul Leong, James D. Firth, John S Carey, Sophie L. Berrell
article en
3 citations

Abstract

In campaign 1, 103.9 kg of (S)-2-(N-benzyl-N-methylamino)-1-propanamine d-tartaric acid salt (4) was prepared in 3 stages from l-alaninamide·HCl. The Stage 2 reaction, the reductive amination of (S)-2-benzylaminopropionamide (2) with aqueous formalin using H2, Pd/C, and THF as solvent, proved to be nonrobust. Ahead of campaign 2, the Stage 2 and 3 processes were redeveloped to provide a higher yielding and more robust set of reaction conditions. The key change was to conduct the reductive amination of (S)-2-benzylaminopropionamide (2) with aqueous formalin using NaBH4 in MeOH as solvent while maintaining a constant pH (pH = 8.5) by the addition of acetic acid. In campaign 2, (S)-2-(N-benzyl-N-methylamino)-1-propanamine was isolated as the d-mandelic acid salt. A total of 373 kg of (S)-2-(N-benzyl-N-methylamino)-1-propanamine d-mandelic acid salt was produced in high yield and excellent quality. (S)-2-(N-Benzyl-N-methylamino)-1-propanamine is a key intermediate in the synthesis of the orexin 1 receptor antagonist C4X3256.

Organic Process Research & Development
The Priory Hospital (GB), Lonza (Switzerland) (CH)
Openalex Percentile: Top 9%
Chemical Synthesis and Analysis
3.78
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon